In several trials, some patients experienced grade 3 or more serious adverse events such as thrombocytopenia, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), and pneumonia. This evidence concerns the gene GPT and susceptibility to pneumonia measurement.